Descripción sociodemográfica y clínica de los pacientes con pénfigo atendidos en el Hospital Universitario De La Samaritana de la ciudad de Bogotá durante los años 2016 a 2020

dc.contributor.advisorCortés Correa, Carolina Ivettespa
dc.contributor.authorCamacho Pérez, Laura Carolinaspa
dc.date.accessioned2021-01-26T19:56:37Zspa
dc.date.available2021-01-26T19:56:37Zspa
dc.date.issued2020-12-16spa
dc.description.abstractObjective: To carry out the epidemiological and clinical description of patients with pemphigus attended at the University Hospital De La Samaritana in the city of Bogota during the years 2016 to 2020. Patients and methods: Observational study, descriptive type series of cases. Includes 21 patients with confirmed diagnosis of pemphigus seen at the Hospital Universitario De La Samaritana during the years 2016 to 2020. Results: The male sex was the most frequent with 52.3%. The mean age was 55 years (SD 17.9 years). The median time of evolution of pemphigus was 7 months (IQR 8.2 months), with an average evolution of the lesions of 12.83 months prior to diagnosis. The most frequent type of pemphigus was vulgar with 47.6%. The anatomical region most compromised by pemphigus was the head with 90.47% and mucosal involvement was present in 71.42% of the cases. In the 21 patients a skin biopsy was performed, being consistent with the diagnosis of pemphigus in 95.23%. The most common biopsy findings were acantholysis in 71.42%, followed by a tumbstones image in 47.61%. Direct immunofluorescence was performed in 20 patients, which corresponds to 95.23% of the sample, being in 17 patients (80.95%) compatible with the diagnosis of pemphigus. 20 patients received topical treatment, 71.42% used an emollient, a corticosteroid in 61.90% and an antibiotic in 9.52%. 21 patients received systemic treatment, in 100% of the cases in which systemic corticosteroid and Azathioprine were used, followed by Rituximab with 42.85% and IV immunoglobulin with 23.8%. Remission was recorded in 42.85% and relapse in 57.14%. There was a mortality of 9.52%spa
dc.description.abstractObjetivo: Realizar la descripción sociodemográfica y clínica de los pacientes con pénfigo atendidos en el Hospital Universitario De La Samaritana de la ciudad de Bogotá durante los años 2016 a 2020. Pacientes y métodos: Estudio observacional, descriptivo tipo serie de casos. Incluye a 21 pacientes con diagnostico confirmado de pénfigo atendidos en el Hospital Universitario De La Samaritana durante los años 2016 a 2020. Resultados: El sexo masculino fue el más frecuente con 52,3%. La media de edad fue de 55 años (DE 17,9 años). La mediana de tiempo de evolución del pénfigo fue de 7 meses (RIQ 8,2 meses), con un promedio de evolucion de las lesiones de 12,83 meses previo al diagnóstico. El tipo de pénfigo más frecuente fue vulgar con 47,6%. La región anatómica más comprometida por el pénfigo fue la cabeza con 90,47% y el compromiso en mucosas estuvo presente 71,42% de los casos. En los 21 pacientes se realizó biopsia de piel, siendo concordante con el diagnostico de pénfigo en el 95,23%. Los hallazgos en la biopsia más comunes fueron acantolisis en el 71,42%, seguido de imagen en lapida en el 47,61%. Se realizó la inmunofluorescencia directa en 20 pacientes lo cual corresponde al 95,23% de la muestra, siendo en 17 pacientes (80,95%) compatibles con el diagnostico de pénfigo. 20 pacientes recibieron tratamiento tópico, en el 71,42% se utilizó emoliente, corticoide en el 61,90% y antibiótico en el 9,52%. 21 pacientes recibieron tratamiento sistémico, en el 100% de los casos se utilizó corticoide sistémico y Azatioprina seguido de Rituximab con 42,85% e inmunoglobulina IV con 23,8%. La remisión se observó en el 42,85% y la recidiva en el 57,14%. Hubo una mortalidad del 9,52%spa
dc.description.degreelevelEspecialidades Médicasspa
dc.format.extent69spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/78928
dc.language.isospaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.programBogotá - Medicina - Especialidad en Dermatologíaspa
dc.relation.references1. Ocampo-Valencia OJ, Velásquez-Lopera MM. Inmunopatogenia del pénfigo vulgar y el pénfigo foliáceo. Iatreia. 2011;24(3):272-286.spa
dc.relation.references2. García-Briz MI, Moneva-Léniz LM, Santos-Alarcón S, Prats-Máñez A, García-Ruiz R, Mateu-Puchades A. Pénfigo: tratamiento y evolución en nuestros pacientes. Piel (Barc., Internet).2019;34(6):344-346.spa
dc.relation.references3. Ujiie I, Ujiie H, Iwata H, Shimizu H. Clinical and immunological features of pemphigus relapse. Br J Dermatol. 2019;180(6):1498-1505.spa
dc.relation.references4. Kidrin K . Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66(2):255-270.spa
dc.relation.references5. Robledo MA, Prada S, Jaramillo D, Leon W. South American pemphigus foliaceus: study of an epidemic in El Bagre and Nechi, Colombia 1982 to 1986. Br J Dermatol. 1988;118(6):737-744.spa
dc.relation.references6. Pinilla García, Ximena Alexandra, et al. Estudio de las características clínicas y epidemiológicas de los pacientes con Enfermedades ampollosas autoinmunes en un hospital de tercer nivel de Bogotá. Tesis Doctoral. Universidad Nacional de Colombia-Sede Bogotá, 2016.spa
dc.relation.references7. Santoro FA, Stoopler ET, Werth VP. Pemphigus. Dent Clin N Am. 2013;57(4):597-610.spa
dc.relation.references8. Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev. 2014;13(4-5):477-481.spa
dc.relation.references9. Meyer N, Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev. 2010;9(5):379-382.spa
dc.relation.references10. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Arch Dermatol Res. 2015; 307(4):291-298.spa
dc.relation.references11. Scully C, Mignogna M. Oral mucosal disease: pemphigus. Br J Oral Maxillofac Surg. 2008;46(4):272-277.spa
dc.relation.references12. Bystryn JC, Rudolph JL. Pemphigus. Lancet. 2005;366(9479):61-73.spa
dc.relation.references13. Ruocco V, Ruocco E, Schiavo AL, Brunetti G, Guerrera LP, Wolf R. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol. 2013;31(4):374-381.spa
dc.relation.references14. Baroni A, Lanza A, Cirillo N, Brunetti G, Ruocco E, Ruocco V. Vesicular and bullous disorders: pemphigus. Dermatol Clin. 2007;25(4):597-603.spa
dc.relation.references15. Tula M. Penfigoide de las mucosas. Dermatol Argent. 2012;18(2):16-23.spa
dc.relation.references16. Aldama A, Aquino N. Pénfigo. Tendencias en Medicina. 2016;11:102-106.spa
dc.relation.references17. Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet. 1999;354(9179):667-672.spa
dc.relation.references18. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29(3):405-412.spa
dc.relation.references19. Peñas PF, Buezo GF, Carvajal I, Daudén E, López A, Díaz LA. D-Penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease. J Am Acad Dermatol.1997;37(1):121-123.spa
dc.relation.references20. Patterson CRS, Davies MG. Pemphigus foliaceus: an adverse reaction to lisinopril. J Dermatolog Treat. 2004;15(1):60-62.spa
dc.relation.references21. Moraes ME, Fernandez-Vina M, Lazaro A, Diaz LA, Filho GH, Friedman H, Rivitti E, et al. An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations. Tissue antigens.1997;49(1):35-40.spa
dc.relation.references22. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004;9(1):29-33.spa
dc.relation.references23. Marini MA, Parra LS, Casas JG. Pénfigo herpetiforme: presentación de un caso y revisión de la literatura. Arch Argent Dermatol.2004;54(3):103-108.spa
dc.relation.references24. Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol. 2014;70(4):780-787.spa
dc.relation.references25. Tsuruta D, Ishii N, Hamada T, Ohyama B, Fukuda S, Koga H, Imamura K, et al. IgA pemphigus. Clin Dermatol. 2011;29(4):437-442.spa
dc.relation.references26. Bahamonde H, Délano PH, Albertz N, Valdés C. Penfigoide cicatricial, causa poco común de estenosis supraglótica. Rev Otorrinolaringol Cir Cabeza Cuello. 2008;68(3):288-294.spa
dc.relation.references27. Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zilikens D, Payne A, Amagai M. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.spa
dc.relation.references28. Joly Pascal, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol. 2011;29(4):432-436.spa
dc.relation.references29. Chan MH, Wolf JC. Biopsy techniques and diagnoses and treatment of mucocutaneous lesions. Dent Clin N Am. 2012;56(1):43-73.spa
dc.relation.references30. Matos-Cruz R, Bascones-Martínez A. Pénfigo: Una revisión de la literatura. Av Odontoestomatol. 2009;25(2):67-82.spa
dc.relation.references31. Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010;10(2):84-89.spa
dc.relation.references32. Rashid H, Lamberts A, Diercks GFH, Pas HH, Meijer JM, Bolling MC, Horváth B. Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm. Am J Clin Dermatol. 2019; 20(6):847-861.spa
dc.relation.references33. Bascones-Martínez A, Munoz-Corcuera M, Bascones-Ilundain C. Patología inmunológica de localización bucal. Med Clin (Barc). 2013;140(2):88-92.spa
dc.relation.references34. Leuci S, Ruoppo E, Adamo D, Calabria E, Mignogna MD. Oral autoimmune vesicobullous diseases: Classification, clinical presentations, molecular mechanisms, diagnostic algorithms, and management. Periodontol 2000. 2019;80(1):77-88.spa
dc.relation.references35. Witte M, Zillikens D, Schmidt E. Diagnosis of Autoimmune Blistering Diseases. Front Med (Lausanne). 2018;5:296.spa
dc.relation.references36. Shetty VM, Subramaniam K, Rao R. Utility of immunofluorescence in dermatology. Indian Dermatol Online J. 2017;8(1):1-8.spa
dc.relation.references37. Pohla-Gubo G, Hintner H. Direct and indirect immunofluorescence for the diagnosis of bullous autoimmune diseases. Dermatol Clin. 2011;29(3):365-372.spa
dc.relation.references38. Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012;30(1):84-94.spa
dc.relation.references39. Tanikawa A, Amagai M. Pemphigus treatment in Japan. Dermatol Clin. 2011;29(4):685-686.spa
dc.relation.references40. Parker SRS, Mackelfresh J. Autoimmune blistering diseases in the elderly. Clin Dermatol. 2011;29(1):69-79.spa
dc.relation.references41. Suárez-Fernández R, España-Alonso A, Herrero-González J, Mascaró-Galy J. Manejo práctico de las enfermedades ampollosas autoinmunes más frecuentes. Actas Dermosifiliogr. 2008;99(6):441-455.spa
dc.relation.references42. Meyer V, Beissert S. Azathioprine in the treatment of autoimmune blistering diseases. Immunol Allergy Clin N Am. 2012;32(2):295-307.spa
dc.relation.references43. Frew JW, Martin LK, Murrell DF. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin. 2011;29,(4):599-606.spa
dc.relation.references44. Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol. 2019;10:1418.spa
dc.relation.references45. Tavakolpour S. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?. Int Immunopharmacol. 2017;53:133-142.spa
dc.relation.references46. Sinha AA, Hoffman MB, Janicke EC. Pemphigus vulgaris: approach to treatment. Eur J Dermatol. 2015;25(2):103-113.spa
dc.relation.references47. Gürcan HM, Razzaque AA. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161(4):723-731.spa
dc.relation.references48. Tóth GG, Jonkman MF. Therapy of pemphigus. Clin Dermatol. 2001;19(6):761-767.spa
dc.relation.references49. Hoffmann JHO, Enk AH. High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease. Front Immunol. 2019;10:1090.spa
dc.relation.references50. Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7(4):529-541.spa
dc.relation.references51. Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Treatment Update of Autoimmune Blistering Diseases. Dermatol Clin. 2019;37(2):215-228.spa
dc.relation.references52. Temel AB, Murrell DF. Pharmacological advances in pemphigus. Curr Opin Pharmacol. 2019;46:44-49.spa
dc.relation.references53. Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low‐dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405-412.spa
dc.relation.references54. Heelan K, Al-Mohammedi F, Smith MJ, Knowles S, Lansang P, Walsh S, Shear N. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol.2014;150(7):703-708.spa
dc.relation.references55. Huan A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris: Rituximab and beyond. J Am Acad Dermatol.2016;74(4):746-753.spa
dc.relation.references56. Culton D.A, Qian Y, Li N et al. Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity. J Autoimmun. 2008;31:311-324.spa
dc.relation.references57. Zuluaga DC, Del Río DY, Úsuga YA, Aguirre-Acevedo DC, Velásquez MM. Estudio retrospectivo clínico-epidemiológico de los pacientes con pénfigo y penfigoide ampolloso del Hospital Universitario San Vicente Fundación. Rev Asoc Colomb Dermatol. 2017;25(2):118-129.spa
dc.relation.references58. Porro AM, Filho GH, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus- Brazilian society of dermatology. An Bras Dermatol. 2019;94(2 suppl 1):S20.32.spa
dc.relation.references59. Hebert V, Boulard C, Houivet E, Duvert-Lehembre S, Borradori L, Della Torre R, Feliciani C, Fania L, Zambruno G, Camaioni DB, et al. Large international validation of ABSIS and PDAI pemphigus severity scores. J Invert Dermatol. 2019; 139(1):31-37.spa
dc.relation.references60. Diercks GF, Pas HH, Jonkman MF. Immunofluorescence of autoimmune bullous diseases. Surg Pathol Clin. 2017;10(2):505-512.spa
dc.relation.references61. Murrell DF, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA, Sinha AA. Diagnosis and management of pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2020;82(3):575-585.e1spa
dc.relation.references62. Kridin K, Patel PM, Jones VA, Cordova A, Amber KT. IgA Pemphigus: a systematic review. J Am Acad Dermatol. 2020;82(6):1386-1392.spa
dc.relation.references63. Cura MJ, Torre AC, Cueto-Sarmiento KY, Bollea-Garlatti ML, Riganti J, Puga MC, Mazzuoccolo LD. Pénfigo vulgar: estudio de cohorte retrospectiva de sus características clínicas, tratamientos empleados y evolución. Actas Dermosifiliogr. 2020;111(5):398-407.spa
dc.relation.references64. Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houvivet E, Calbo S, Caillot F, et al. First-line rituximab combined with short- term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomized trial. Lancet. 2017;389:2031-2040.spa
dc.relation.references65. Kim JH, Kim SC. Paraneoplastic pemphigus: Paraneoplastic autoimmune disease of the skin and mucosa. Front Immunol. 2019;10:1259.spa
dc.relation.references66. Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol. 2002;147(4):725–32.spa
dc.relation.references67. Marathe K, Lu J, Morel KD. Bullous diseases: Kids are not just little people. Clin Dermatol. 2015;33(6):644–56.spa
dc.relation.references68. Schultz B, Hook K. Bullous Diseases in Children: A Review of Clinical Features and Treatment Options. Pediatr Drugs. 2019;21(5):345–56.spa
dc.relation.references69. Ñahui-Conza M. Características clínico epidemiológicas de las enfermedades ampollares autoinmunes en el Hospital Nacional Guillermo Almenara Irigoyen- EsSalud, durante el periodo comprendido de junio de 1999 a mayo de 2009. Trabajo de investigación Universidad Nacional Mayor de San Marcos.spa
dc.relation.references70. Ren Z, Narla S, Hsu DY, Silverberg JI. Association of serious infections with pemphigus and pemphigoid: analisis of the Nationwide inpatient sample. J Eur Acad Dermatol Venereol. 2018;32(10):1768-1776.spa
dc.relation.references71. Sobhan M, Farshchian M, Tamimi M. Spectrum of autoinmune vesicobullous diseases in Iran: a 13-year retrospective study. Clinical, Cosmetic and Investigational Dermatology 2016; 9: 15-20.spa
dc.rightsDerechos reservados - Universidad Nacional de Colombiaspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacionalspa
dc.rights.spaAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.subject.ddc610 - Medicina y salud::616 - Enfermedadesspa
dc.subject.proposalPénfigo vulgarspa
dc.subject.proposalPemphigus vulgariseng
dc.subject.proposalPemphigus foliaceuseng
dc.subject.proposalPénfigo foliáceospa
dc.subject.proposalRituximabspa
dc.subject.proposalRituximabeng
dc.subject.proposalEpidemiologyeng
dc.subject.proposalEpidemiologíaspa
dc.titleDescripción sociodemográfica y clínica de los pacientes con pénfigo atendidos en el Hospital Universitario De La Samaritana de la ciudad de Bogotá durante los años 2016 a 2020spa
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
1140837718.2020.pdf
Tamaño:
737.55 KB
Formato:
Adobe Portable Document Format

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
3.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción: